Sweden-based Orexo AB is making organisational and management changes following the divestment of its product zubsolv in the US market and the focus on advancing its pipeline and amorphOX drug delivery technology. Orexo has appointed Lisa Moore, who has been part of the US leadership team since May 2024, as senior vice president, products and portfolio strategy. Robert DeLuca, president of Orexo US Inc, is retiring from the company. He will remain in his role through May 2026 and after that will have an advisory role. Ms Moore will report to Orexo’s chief executive officer and will be responsible for driving long-term vision for development candidates, ensuring that the portfolio meets customer needs and that investment decisions support business growth. Prior to joining Orexo, she was vice president, global commercial strategy at Emergent, where she also led the commercial valuation of M&A opportunities.
Orexo announced the appointment on 6 March 2026.
Copyright 2026 Evernow Publishing Ltd.